Targeted Genetics (NASDAQ:TGEND)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Targeted Genetics Charts. Click Here for more Targeted Genetics Charts.](/p.php?pid=staticchart&s=N%5ETGEND&p=8&t=15)
Presentations Include Preliminary Data from an Ongoing Phase I/II
Trial of tgAAC94 in Patients with Inflammatory Arthritis and 13
Additional Abstracts
Targeted Genetics Corporation (Nasdaq:TGEND) and its academic and
corporate collaborators will report data in 14 presentations at the
9th Annual Meeting of the American Society of Gene Therapy (ASGT). The
meeting will take place June 1 - June 5 in Baltimore, Maryland. Two
presentations will discuss preliminary safety and efficacy data from
an ongoing Phase I/II clinical trial of tgAAC94 in patients with
inflammatory arthritis, and two additional presentations will describe
other advances in the company's inflammatory disease program. Research
conducted by Dr. John Engelhardt, Ph.D., Director of the Center for
Gene Therapy, and Professor, Department of Anatomy and Cell Biology,
at the University of Iowa, and funded by Targeted Genetics, will be
featured as one of the "Top Five Abstracts" at the Presidential
Symposium on June 3rd (Abstract # 807). Additional presentations will
focus on advances in AAV manufacturing, basic and applied AAV biology
and Targeted Genetics' collaborations in the areas of Huntington's
disease and congestive heart failure.
"As a company committed to developing cutting-edge therapies for
diseases with significant unmet medical need, we recognize the
importance of advancing both the science and the commercial potential
of AAV-based therapies," said H. Stewart Parker, president and chief
executive officer of Targeted Genetics. "These presentations at ASGT
reflect our success in both of these endeavors. We are making
significant progress in our product development programs in the areas
of inflammatory disease, Huntington's disease and congestive heart
failure, while also enhancing our manufacturing capabilities. Our
commercial activities are built on a solid foundation of AAV biology,
and we are pleased to share the advances that we and our collaborators
have made in this area with the gene therapy community."
Presentations relevant to Targeted Genetics' product development
programs are:
Preliminary Phase I/II data from an ongoing trial of tgAAC94 in
patients with inflammatory arthritis:
Workshop 225:
Musculo-Skeletal: Gene Expression and Immunology of
Musculoskeletal Gene Therapy "Clinical Development of an AAV Vector
Expressing the TNF Receptor: Fc Fusion Gene in Inflammatory
Arthritis." Oral presentation -- Thursday, June 1.
Abstract #1092
"Clinical Studies of Intra-Articular Administration of a
Recombinant Adeno-Associated Vector Contain a TNF-alpha Antagonist
Gene in Inflammatory Arthritis." Oral Presentation -- Sunday, June 4.
Inflammatory arthritis preclinical data:
Abstract #578
"Suppression of Inflammation Following Intramuscular
Administration of Pseudotyped AAV-TNFR:Fc Vectors in a Rat Model of
Arthritis." Poster Presentation -- Friday, June 2.
Abstract #983
"Repeat Intra-Articular Administration of AAV2 Vectors to Rat
Joints." Poster Presentation -- Saturday, June 3.
AAV Manufacturing:
Abstract #312
"Clearance of Helper Adenovirus by an AAV1 Clinical Vector
Manufacturing Process." Poster Presentation -- Thursday, June 1.
Abstract #499
"Improving the Stability of Ad-AAV Hybrid Vectors." Poster
Presentation -- Friday, June 2.
Huntington's Disease:
Abstract #414
"Non-Allele Specific RNA Interference in the CAG140 Knock-In Mouse
Model of Huntington's Disease." Oral Presentation -- Friday, June 2.
Congestive Heart Failure:
Abstract #557
"A Study of AAV2/1/SERCA2a Delivered Via the V-Focus Cardiac
Delivery System in an Ovine Pacing Model of Heart Failure." Poster
Presentation -- Friday, June 2.
AAV Biology:
Abstract #1
"Species Choice for Animal Modeling Cystic Fibrosis and Gene
Therapy in the Airway." Oral presentation -- Thursday, June 1.
Abstract #10
"Adeno-Associated Virus Type-1 Vectors Transduce Human Polarized
Airway Epithelia without Polarity Preference." Oral Presentation --
Thursday, June 1.
Abstract #106
"rAAV2 Traffics through Both the Late and Recycling Endosomes in a
Dose-Dependent Fashion." Poster Presentation -- Thursday, June 1.
Abstract #118
"In Vivo Tracking of Long Term Gene Expression of AAV1 Using
Fluorescence Imaging System." Poster Presentation -- Thursday, June 1.
Abstract #492
"Biodistribution and Integration Assessment of AAV1
gag-PR-RT((delta)RnaseH) after Intramuscular Administration in
Rabbits." Poster Presentation -- Friday, June 2.
Abstract #807
"NADPH-Dependent Endosomal ROS is Critical for rAAV Capsid
Processing During Infection." Oral Presentation -- Saturday, June 3.
For more information about the 9th Annual Meeting of the American
Society of Gene Therapy, please refer to www.asgt.org.
About Targeted Genetics
Targeted Genetics Corporation is a biotechnology company committed
to the development and commercialization of innovative, targeted
molecular therapies for the prevention and treatment of inflammatory
arthritis, HIV/AIDS and other acquired and inherited diseases with
significant unmet medical need. Targeted Genetics uses its
considerable knowledge and capabilities in the development and
manufacturing of gene delivery technologies to advance a diverse
product development pipeline. Its product development efforts target
inflammatory arthritis, HIV/AIDS, congestive heart failure,
Huntington's disease, and hyperlipidemia. To learn more about Targeted
Genetics, visit its website at www.targetedgenetics.com.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995:
This release contains forward-looking statements regarding our
potential development platforms including AAV vectors, the data to be
collected in our clinical trials, the establishment or determination
of efficacy endpoints from the data collected in our clinical trials,
the timely and complete accrual of patients in the our clinical
trials, our ability to commercialize any of our products in clinical
trials, our ability to produce our product candidates at large scale
commercial production and other statements about our plans,
objectives, intentions and expectations. These statements, involve
current expectations, forecasts of future events and other statements
that are not historical facts. Inaccurate assumptions and known and
unknown risks and uncertainties can affect the accuracy of
forward-looking statements. Factors that could affect our actual
results include, but are not limited to, results of animal research
are not necessarily indicative of results in humans, the timing,
nature and results of our research, potential development of
alternative technologies or more effective products by competitors,
our ability to recruit and enroll suitable trial participants, our
ability to obtain and maintain regulatory or institutional approvals,
our ability to obtain, maintain and protect our intellectual property
and our ability to raise capital when needed, as well as other risk
factors described in Item 1A. Risk Factors in our report on Form 10-K
for the year ended December 31, 2005, and updated in Item 1A. Risk
Factors in our Form 10-Q for the quarter ended March 31, 2006. You
should not rely unduly on these forward-looking statements, which
apply only as of the date of this release. We undertake no duty to
publicly announce or report revisions to these statements as new
information becomes available that may change our expectations.